The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC Sept 2021 | Efficacy of mobocertinib in patients previously treated with TKIs
Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, Fairfax, VA, presents data from the expansion cohort of the Phase I/II study (NCT02716116) evaluating mobocertinib in patients with non-small cell lung cancer (NSCLC), which included patients pre-treated with tyrosine kinase inhibitors (TKIs). Although the cohort’s sample size was relatively small, it suggested that mobocertinib is more efficacious than other TKIs. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.
